Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
about
Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant TumoursChanges in laminin isoforms associated with brain tumor invasion and angiogenesisMelanoma: new insights and new therapiesProteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cellsRecent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.A novel concept for ligand attachment to oligonucleotides via a 2'-succinyl linker.High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides.Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.Identification of differentially expressed sense and antisense transcript pairs in breast epithelial tissues.Targeted therapy in melanoma.Transcription therapy for cancer.Disruption of the VDAC2-Bak interaction by Bcl-x(S) mediates efficient induction of apoptosis in melanoma cells.Drug-resistance in human melanoma.Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaA pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC.Isolated amelanotic malignant melanoma of the heart.Role of Bcl-2 family of proteins in malignancy.Molecular and pharmacological strategies to overcome multidrug resistance.The emergence of resistance to targeted cancer therapeutics.G3139 (Genasense) in patients with advanced merkel cell carcinomaTargeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.Overview of the clinical efficacy of investigational anticancer drugs.In vivo imaging with oligonucleotides for diagnosis and drug development.Mitochondria as a target for inducing death of malignant hematopoietic cells.Novel pharmacological approaches in the treatment of breast cancer.Gene-expression profiling in human cutaneous melanoma.Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.An introduction to the molecular mechanisms of apoptosis.Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia.On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Biomarkers in melanoma: stage III and IV disease.Antisense therapy for cancer.Novel agents in development for the treatment of melanoma.RNA interference for treating haematological malignancies.Cutaneous melanoma: available therapy for metastatic disease.Molecular mediators of cell death in multistep carcinogenesis: a path to targeted therapy.Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells.Lack of clinical efficacy of imatinib in metastatic melanoma
P2860
Q21284986-8B2A7FAF-6350-47B7-B860-5E2B5D20D6AAQ24607083-59CE6C3F-0FB2-4E03-A43E-3E9952362F31Q26853127-3C6D505E-92D9-4FA4-9ADD-C45BE68ABFE8Q28534817-F223A058-5289-47E4-886F-DF4CF6DDF3BFQ30971455-DD1E5C18-9AC4-416B-B306-FFDB4BE437DAQ33197337-2B1E85F7-4F28-4720-9B85-CFD0F319383DQ33285354-D0747ED8-5E79-4155-83B4-5FD84E645C13Q33403800-E3B39879-D54A-4657-AB63-7E9345BEFEBCQ33483666-C5995CFA-91D8-4E17-BF66-58CBA505A4FBQ33573107-0E7DD5AF-EC5B-45F1-8BEA-5BE2A1C2102BQ34290301-755E7B72-7F25-4C37-8BF3-2C0145A1DAF1Q34306986-DCDF4914-5521-4B4A-9A70-AE64901471BBQ34321923-4C1286EB-3FD5-4801-B4B0-E3686825CEEBQ34366036-11AF8E85-A525-44E1-A578-726F69E8E7A8Q34497045-CC67EEA1-60D1-4EE0-87CE-139BB2D6CB4EQ34624645-293A8179-8BF9-4EEB-8FEA-5B84A3D855B1Q34631286-CF7C4A0E-2CE5-43C4-9320-F0C6B8824A18Q34733047-7F8D11A3-C63E-4068-808C-F27D301FCFA6Q34734178-5E286C8A-7D48-4E00-80C1-361B4450C623Q34837015-418E404F-C528-4574-A5AA-38353C436F9FQ35029577-BB190D50-1CD9-415B-A5F9-D9CA71C726D9Q35052161-88883477-F25B-4911-B47E-D9C1FCB6B59EQ35067125-74A4F72D-C6BC-43A0-BBDD-879704ED123CQ35127223-8646AE41-27D9-43B3-B30D-918FF736F0F2Q35137160-5060CF1B-7130-4CFB-A73B-1EFD29CAD313Q35143980-D6A19018-CE2E-4822-A3F4-E37296FDA04DQ35146553-2EB0EA31-77E1-445D-B1C7-93F65CAADC8EQ35185012-A46CFCDB-94C8-49EF-91E6-CB67D306AD82Q35222636-C806C905-6623-49FB-9F0B-D2FC4786A48AQ35700262-17C53C4B-2BA6-4A1D-9872-679C27023E42Q35854960-9C72F38C-8A10-4459-ACDB-C47922C91990Q35854970-C2D28CCC-6593-451F-8396-A2A7E8D0B000Q36050541-E3114017-0361-4A3D-BF02-3776CE63D138Q36133133-639B40BA-96B2-4283-93C8-204197DDBFB1Q36196484-AD1F2AA3-938F-49F0-9D03-33756FD215ECQ36327055-A0E02A31-8054-49D7-BD28-509FC2C96B0FQ36365463-597E4A0D-7885-45AC-B2E5-B36711DBA458Q36501198-6AE57209-4205-49E1-9D5E-AF9071334762Q36526103-8016CF04-AFDE-48E8-8D23-D894E96D0422Q36616712-AE9770D5-3E18-4D6D-8047-082649E646C2
P2860
Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
@en
type
label
Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
@en
prefLabel
Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
@en
P2093
P1433
P1476
Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
@en
P2093
E Heere-Ress
H Pehamberger
H Schlagbauer-Wadl
M Hoermann
U Hollenstein
P304
P356
10.1016/S0140-6736(00)03207-4
P407
P577
2000-11-01T00:00:00Z